Euan Posted November 4, 2011 Share Posted November 4, 2011 An experimental drug known as MDV3100 made by Medivation Inc. has improved survival rates for men with metastatic castration-resistant prostate cancer. Those on MDV3100 by Medivation outlived those on a placebo by an average of 4.8 months, in a phase 3 trial. The manufacturer Medivation Inc. shares shot up 150% on the news and they announced that an independent committee monitoring the trial recommended stopping the trial after reviewing interim results. It would be unfair and arbitrary to those on the placebo, to continue just for the sake of gathering relatively unneeded data. http://www.medicalne...cles/237110.php Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.